Offering new hope
in the battle against antibiotic
resistant bacteria

Welcome to Auspherix

Auspherix is an anti-infectives company that is developing a novel class of organogold-based antibiotics that are designed to help address the worldwide healthcare crisis of rising antimicrobial resistance (AMR).

Research & Development

Our proprietary organogold chemistry platform is being used to build a pipeline of novel antibacterials with an initial therapeutic focus on complicated urinary tract (cUTI) infections.

read more »

Partnering

Whilst Auspherix is committed to progressing its pipeline of organogold compounds into clinical development, it welcomes strategic partnering opportunities with pharma and biotech companies in the anti-infectives space to expand its R&D capabilities and pipeline.

read more »

Investors

Auspherix is a private biotechnology company that is backed by leading sector investors namely Brandon Capital through the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations.

read more »

Auspherix to Present Organogold Pipeline at Superbugs & Superdrugs

Stevenage, UK – 20 March 2017 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017. Chief Scientific Officer Richard Rutter will […]

Auspherix Provides Update on its New Class of Organogold Antibiotics

Stevenage, UK – 5 January 2016 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today provided an update on its organogold chemistry platform and its pipeline of compounds. Auspherix’s new class of antibiotics are differentiated from current antibiotics by their chemical structure and distinct […]

December 2016 – PharmaVentures TV

Interview with CEO, Dr Neil Miller, discussing how Auspherix is meeting the urgent need for new antibiotics by developing a new class of organogold antibiotics.

View video on the PharmaVentures TV website

November – MedNous

Interview with CEO, Dr Neil Miller in an article about “The Stately Progress of Antibiotics”.

View PDF

November 2016 – Scrip TV

Interview with CEO, Dr Neil Miller.

Latest Tweets